Emergent Biosolutions, Inc. (EBS)

Price$8.49

Value ScoreA

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-15.49%

Price vs S&P 500 (4W)2.70%

VGM Score51.03

Market Capitalization$451.47M

P/E Ratio (Annual)8.58x

All Metrics

P/CF (Annual)2.65x

Book Value / Share (Quarterly)$10.10

P/TBV (Annual)7.54x

Revenue Growth (3Y)-12.81%

Cash Flow / Share (Quarterly)$2.61

Price vs S&P 500 (YTD)-37.15%

Gross Margin (TTM)54.26%

Net Profit Margin (TTM)-1.27%

EPS (TTM)$-0.24

10-Day Avg Trading Volume0.81M

EPS Excl Extra (TTM)$-0.24

Revenue Growth (5Y)-13.74%

EPS (Annual)$0.93

ROI (Annual)4.80%

Gross Margin (Annual)56.09%

Net Profit Margin (5Y Avg)-18.06%

Cash / Share (Quarterly)$3.09

P/E Basic Excl Extra (TTM)9.41x

Revenue Growth QoQ (YoY)-29.75%

EPS Growth (5Y)-30.38%

P/E Normalized (Annual)8.58x

ROA (Last FY)3.99%

Revenue Growth TTM (YoY)-29.89%

EBITD / Share (TTM)$2.30

ROE (5Y Avg)-29.65%

Operating Margin (TTM)8.97%

Cash Flow / Share (Annual)$3.01

P/B Ratio0.86x

P/B Ratio (Quarterly)0.82x

Net Income / Employee (Annual)$58,400

EV / Revenue (TTM)1.28x

Net Interest Coverage (TTM)2.40x

ROA (TTM)-0.62%

EPS Growth QoQ (YoY)-89.85%

EV / EBITDA (TTM)6.86x

EPS Incl Extra (Annual)$0.93

Current Ratio (Annual)5.01x

Quick Ratio (Quarterly)1.90x

3-Month Avg Trading Volume0.83M

52-Week Price Return41.18%

EV / Free Cash Flow (Annual)5.52x

P/E Incl Extra (TTM)9.41x

Revenue / Employee (TTM)$752,000

Tangible BV / Share (Quarterly)$1.02

P/S Ratio (Annual)0.61x

Asset Turnover (Annual)0.56x

52-Week High$14.06

Operating Margin (5Y Avg)-10.91%

EPS Excl Extra (Annual)$0.93

CapEx CAGR (5Y)-38.03%

Tangible BV CAGR (5Y)-24.31%

26-Week Price Return0.44%

Quick Ratio (Annual)2.22x

13-Week Price Return-17.84%

Total Debt / Equity (Annual)1.09x

Current Ratio (Quarterly)4.29x

Enterprise Value$864.77M

Revenue / Share Growth (5Y)-14.64%

Asset Turnover (TTM)0.49x

Book Value / Share Growth (5Y)-18.12%

Revenue / Employee (Annual)$825,400

Inventory Turnover (Annual)1.00x

Pretax Margin (Annual)11.15%

Cash / Share (Annual)$3.94

3-Month Return Std Dev72.75%

Gross Margin (5Y Avg)43.73%

Net Income / Employee (TTM)$-9,600

EBITDA CAGR (5Y)-20.88%

EBITDA Interim CAGR (5Y)-24.53%

ROE (Last FY)10.07%

Net Interest Coverage (Annual)1.06x

EPS Basic Excl Extra (Annual)$0.93

P/FCF (TTM)2.55x

Receivables Turnover (TTM)4.16x

EV / Free Cash Flow (TTM)6.39x

Total Debt / Equity (Quarterly)1.10x

EPS Incl Extra (TTM)$-0.24

Receivables Turnover (Annual)6.22x

ROI (TTM)-0.74%

P/S Ratio (TTM)0.67x

Pretax Margin (5Y Avg)-14.97%

Revenue / Share (Annual)$13.10

Tangible BV / Share (Annual)$1.65

Forward P/E26.12x

Free OCF CAGR (5Y)-16.44%

Price vs S&P 500 (52W)12.97%

P/E Ratio (TTM)9.41x

Year-to-Date Return-26.21%

5-Day Price Return7.93%

EPS Normalized (Annual)$0.93

ROA (5Y Avg)-10.14%

Net Profit Margin (Annual)7.08%

Month-to-Date Return10.81%

Cash Flow / Share (TTM)$-9.38

EBITD / Share (Annual)$2.70

Operating Margin (Annual)11.83%

LT Debt / Equity (Annual)1.09x

P/CF (TTM)3.05x

ROI (5Y Avg)-12.17%

P/E Excl Extra (TTM)9.41x

LT Debt / Equity (Quarterly)1.10x

EPS Basic Excl Extra (TTM)$-0.24

P/TBV (Quarterly)8.13x

P/B Ratio (Annual)1.24x

Inventory Turnover (TTM)0.97x

Pretax Margin (TTM)0.52%

Book Value / Share (Annual)$10.03

Price vs S&P 500 (13W)-27.58%

Net Margin Growth (5Y)-18.44%

Beta2.37x

P/FCF (Annual)2.88x

Revenue / Share (TTM)$11.98

ROE (TTM)-1.59%

52-Week Low$5.62

vGradeA

gGradeF

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.21est. -0.25

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
EBSEmergent Biosolutions, Inc.	A	F	C	$8.49
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Emergent BioSolutions develops and manufactures pharmaceutical products and medical countermeasures for public health markets. The company operates three main segments: commercial respiratory products including NARCAN and KLOXXADO nasal sprays; government-contracted medical countermeasures such as anthrax and smallpox vaccines; and bioservices. Revenue is primarily derived from the U.S. market.